Pulmonary Malignant Tumor
Conditions
Interventions
Low-dose group:110-130Gy
Middle dose group:>130-150Gy
High dose group:>150-180Gy
Sponsors
Third Clinical School of Xinjiang Medical University (Affiliated Tumor Hospital)
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-85 years; 2. Intrapulmonary lesions confirmed by organization/cytological biopsy for malignant tumoror primary lesions confirmed by organization/cytological biopsy for malignant tumor, imaging examination of intrapulmonary metastasis; 3. Metastatic lesion 1 to 8cm diameter; 4. Eastern Cooperative Oncology Group (ECOG) performance status score 0-3; 5. Expected lifetime=3 months; 6. Unable to accept surgical treatment; 7. Willingness and to be able to complete the study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. History of radiation therapy for intrapulmonary target lesions; 2. Hypohepatia and renal inadequacy: Child-Pugh classification grade C, glomerular filtration rate451umol/Lendogenous creatinine clearance rate20s, activated partial thromboplastin time>55s, thrombin time>21sprothrombin time-international normalized ratio>2.5; 4. Hemoglobin<9g/dL, white blood cell count<2.5×10^9/Lneutrophil count<1.5×10^9/Lplatelet count<50×10^9/L; 5. ECOG 4;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Local control rate;side reaction; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival; | — |
Countries
China
Contacts
Public ContactWukui Huang
Third Clinical School of Xinjiang Medical University (Affiliated Tumor Hospital)
Outcome results
None listed